The FDA requires some drugs that have already been approved to undergo additional clinical trials in order to confirm safety and effectiveness. These ‘postmarket’ trials are frequently used in cases where Phase 3 trials were too brief to establish safety and effectiveness to the degree of confidence that the FDA ordinarily requires (as with Accelerated Approval drugs).